Clinical Research

Post Graduation in Life- Science with PG Diploma in Clinical Research is Mandatory. Experience as Clinical research Mandatory.

Will be responsible for overall administration of Ind-CEPI activities at THSTI. This will involve coordinating the construction and usage of shared infrastructure facilities at THSTI, leading regional networking and capacity building with LMIC’s and CEPI support from the Project Management Unit in oversight of the RFPs selected for funding etc

Coordinate in screening, Audio-Video consenting, enrolment, periodic study visits and close out visit. Ensure that rights and well-being of a research participant is protected throughout the duration of the study.

Neoadjuvant chemotherapy followed by Surgery versus Surgery followed by adjuvant chemotherapy for resectable Gastric adenocarcinoma- Phase 3-Multicentre Randomized Controlled Trial. Graduate in Life Sciences, M.Sc. Clinical Research, Allied Health Sciences, Biotechnology.

MSc in Clinical Research or Master in Dental Surgery or Master in Public Health with 1 year post qualification experience in the field of Research or Data handling or Manuscript writing. Prior experience in implementing health projects and/or engaging multiple stake holders and partners, including international agencies. 

Master degree in Pharmacy, Clinical Pharmacology, Pharmacy Practice, and Clinical Research preferably with diploma in clinical research from the recognised institute.

Developing Precision Immunotheraphy for Value –Based Treatment of Lung Cancer in India. Graduate, Post Graduate in Life Science with a Diploma in clinical Research. MSC in Clinical Research. 1 - 2 years of experience in Project Management is Mandatory. Experience in drafting of study progress and fund utilization reports is Desirable.

First-class in Masters in Clinical Research, Clinical Trials including an integrated masters degree, or Second class in Masters in Clinical Research, Clinical Trials including an integrated Masters degree with a PhD in Clinical Research, Clinical Trials, Epidemiology.

An open–label phase II trial evaluating the activity and safety of JDQ443 single agent as first-line treatment for patients with locally advanced or metastatic KRAS G12Cmutated non-small cell lung cancer